AG2304 vs Rosuvamibe

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline

AG2304

Developed by Ahn-Gook Pharmaceutical

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule (combination)
Partial signal

NCT06717360 · Phase 3 · completed

The study randomly assigned 158 participants and used quadruple masking with AG2304R as an active comparator. Its primary endpoint was LDL-C, a surrogate biomarker, and the outcome comparison cannot yet be assessed because results are not posted.

No aligned efficacy figure on record for this race.

Rosuvamibe

Marketed by Yuhan Corporation and partners

small molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAG2304Rosuvamibe
LDL-C, % change—Not posted · NCT06717360—Not reported
Non-HDL-C, % change—Not posted · NCT06717360—Not reported
ApoB, % change—Not posted · NCT06717360—Not reported
Lp(a), % change—Not posted · NCT06717360—Not reported
3-point MACE (% with event)—Not posted · NCT06717360—Not reported

LDL-C, % change

AG2304
—Not posted · NCT06717360
Rosuvamibe
—Not reported

Non-HDL-C, % change

AG2304
—Not posted · NCT06717360
Rosuvamibe
—Not reported

ApoB, % change

AG2304
—Not posted · NCT06717360
Rosuvamibe
—Not reported

Lp(a), % change

AG2304
—Not posted · NCT06717360
Rosuvamibe
—Not reported

3-point MACE (% with event)

AG2304
—Not posted · NCT06717360
Rosuvamibe
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AG2304: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Rosuvamibe: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AG2304's landscape · Rosuvamibe's landscape